Abstract
679 Background: Tamoxifen use has been associated with higher levels of serum VEGF. Increased VEGF levels are associated with adverse prognostic markers in women with breast cancer suggesting tamoxifen efficacy might be further improved if VEGF levels could be decreased. Aspirin reduces tissue VEGF production through the inhibition of cyclooxygenase. Aspirin also decreases platelet activation and may decrease the release of VEGF from platelets stimulated in the tumor microenvironment. We examined the effect of short term aspirin use on circulating VEGF levels in women on tamoxifen therapy. Methods: Twelve women receiving tamoxifen for stage 1-4 breast cancer or DCIS were prospectively evaluated. Patients were treated with 325 mg aspirin daily for a total duration of 45 days. Circulating VEGF (plasma, serum) was measured prior to aspirin initiation, following 30 and 45 days on aspirin and 30 days after discontinuation of aspirin. The ability of aspirin to inhibit release of VEGF from platelets was also com...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
